The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

The discovery of ERβ in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERα, but by two balancing factors, ERα and ERβ, which are often antagonistic to one another. Excitingly, ERβ has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERβ by drugs against various diseases. In this review, focus is on the role of ERβ in malignant diseases where the anti proliferative activity of ERβ gives hope of new therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalBiochemical and Biophysical Research Communications
Volume396
Issue number1
DOIs
StatePublished - May 21 2010

Keywords

  • Antiproliferative
  • Cancer
  • Drug
  • Gene expression
  • Nuclear receptor
  • Pharmaceutical
  • Transcription

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Fingerprint

Dive into the research topics of 'The role of estrogen receptor β (ERβ) in malignant diseases-A new potential target for antiproliferative drugs in prevention and treatment of cancer'. Together they form a unique fingerprint.

Cite this